Latest / Applied Clinical Trials
ACT Brief: Signal Durability Redefines RBQM, AI Targets Startup Friction, and CDMOs Advance Patient-Centric Formulation
In today’s ACT Brief, we look at why durable signal closure is emerging as a defining metric in risk-based quality management, how AI can reduce startup delays without burdening sites, and how patient-centric drug design is reshaping the CDMO landscape.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.